Capricor Therapeutics (CAPR) expects its San Diego manufacturing facility for Deramiocel, a treatment for Duchenne muscular dystrophy, will meet license requirements following an early inspection by the US Food and Drug Administration.
The inspection resulted in routine observations related to quality systems and documentation, but no major changes to the facility or manufacturing process were required, the company said Wednesday in a statement.
Deramiocel's Biologics License Application remains under FDA priority review, with a target approval decision set for Aug. 31. A late-cycle meeting is planned for mid-July, and the FDA advisory committee will meet on July 30.
Capricor's shares fell 1.4% in recent trading Wednesday, paring earlier losses.
Price: 13.70, Change: -0.19, Percent Change: -1.37
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。